Participants
From a total population of 233 HAE patients recruited from four academic expert centers in Israel, 197 patients (84.5%) agreed to participate in a preliminary survey, addressing their medical, ethnic, socio-economic background, demographics, and health-related items. Out of these, 66 physican-diagnosed HAE patients consented and qualified to join the study (Table II). Main inclusion criteria were: confirmed diagnosis of HAE based on personal and family history of angioedema attacks; antigenic C1-INH below normal range; and/or functional C1-INH <50% and complement C4 below normal range (Type I). Patients with normal antigenic C1-INH, low functional C1-INH and low C4 (Type II) were also included. Angioedema patients with normal C1-INH and normal C4 were excluded. Only Hebrew-speaking patients participated in the study. The study was approved and supervised by the ethics committees of Tel-Aviv University, Sheba Medical Center and Barzilai Medical center. All patients signed an informed-consent form (ICF). Mean age of participants was 32.4 years (SD ±16.4), Median age 30.0 years (age range 10-70(. 22.3% were children and adolescents and 59.1% were females (Table II).